EA016434B1 - Нанодисперсия - Google Patents

Нанодисперсия Download PDF

Info

Publication number
EA016434B1
EA016434B1 EA201070793A EA201070793A EA016434B1 EA 016434 B1 EA016434 B1 EA 016434B1 EA 201070793 A EA201070793 A EA 201070793A EA 201070793 A EA201070793 A EA 201070793A EA 016434 B1 EA016434 B1 EA 016434B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanodispersion
acid
salts
derivatives
paclitaxel
Prior art date
Application number
EA201070793A
Other languages
English (en)
Russian (ru)
Other versions
EA201070793A1 (ru
Inventor
Аджай Джайсингх Кхопаде
Субхас Баларам Бховмик
Н. Арулсудар
Original Assignee
Сан Фарма Адвансед Ресёрч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA016434(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сан Фарма Адвансед Ресёрч Компани Лимитед filed Critical Сан Фарма Адвансед Ресёрч Компани Лимитед
Publication of EA201070793A1 publication Critical patent/EA201070793A1/ru
Publication of EA016434B1 publication Critical patent/EA016434B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
EA201070793A 2007-12-24 2008-12-23 Нанодисперсия EA016434B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2527MU2007 2007-12-24
PCT/IN2008/000857 WO2009087678A2 (en) 2007-12-24 2008-12-23 Nanodispersion

Publications (2)

Publication Number Publication Date
EA201070793A1 EA201070793A1 (ru) 2010-12-30
EA016434B1 true EA016434B1 (ru) 2012-04-30

Family

ID=40853553

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070793A EA016434B1 (ru) 2007-12-24 2008-12-23 Нанодисперсия

Country Status (20)

Country Link
US (2) US8586062B2 (es)
EP (2) EP2231144B1 (es)
JP (2) JP5656643B2 (es)
KR (1) KR101505419B1 (es)
CN (1) CN101909614B (es)
AP (1) AP2895A (es)
AU (1) AU2008346121B2 (es)
BR (1) BRPI0821514B8 (es)
CA (1) CA2710525C (es)
CO (1) CO6290681A2 (es)
DK (1) DK2231144T3 (es)
EA (1) EA016434B1 (es)
ES (1) ES2509490T3 (es)
IL (1) IL206584A0 (es)
MX (1) MX2010007076A (es)
NZ (1) NZ586343A (es)
PL (1) PL2231144T3 (es)
UA (1) UA100543C2 (es)
WO (1) WO2009087678A2 (es)
ZA (1) ZA201004450B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010261342A1 (en) * 2009-06-19 2012-01-19 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CN102078300B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 托拉塞米脂质体固体制剂
CN102366409B (zh) * 2011-09-14 2013-03-20 海南灵康制药有限公司 一种尼扎替丁脂质体固体制剂
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
BR112015022231B1 (pt) * 2013-03-14 2020-11-24 Griffith Laboratories International, Inc. Metodo para tratamento de fungos que causam sigatoka negra em plantaqoes da familia musaceae
WO2015184238A1 (en) * 2014-05-30 2015-12-03 Oms Investments, Inc. Nano-sized water-based dispersion compositions and methods of making thereof
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
JP2018516964A (ja) * 2015-06-09 2018-06-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
CN107551390A (zh) * 2017-08-21 2018-01-09 常熟佳禾生物科技有限公司 一种用于治疗乳腺小叶增生的中药文胸贴片及其制备方法
US11679124B2 (en) * 2018-03-19 2023-06-20 Epicyt Pharma Ab Composition for use in the treatment of conditions caused by calcium deficiency
US11877717B2 (en) 2019-12-17 2024-01-23 Emma Ruccio Method and apparatus for detecting scoliosis
US11423574B2 (en) 2019-12-17 2022-08-23 Emma Ruccio Method and apparatus for detecting scoliosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021174A1 (en) * 1999-09-23 2001-03-29 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
WO2003077882A2 (en) * 2002-03-18 2003-09-25 Labopharm Inc. Preparation of sterile stabilized nanodispersions
WO2004039351A2 (en) * 2002-10-31 2004-05-13 Maria Rosa Gasco Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US20060188566A1 (en) * 2005-02-24 2006-08-24 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018A (en) * 1849-01-09 Improvement in bog-cutters
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
TWI230616B (en) * 2000-09-25 2005-04-11 Ind Tech Res Inst Liposome for incorporating large amounts of hydrophobic substances
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
DE10124952A1 (de) * 2001-05-21 2002-12-12 Bayer Ag Verfahren zur Herstellung von Nanodispersionen
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050288521A1 (en) * 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
KR20080030024A (ko) 2005-06-17 2008-04-03 호스피라 오스트레일리아 피티와이 리미티드 도세탁셀의 약제학적 액상제제
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021174A1 (en) * 1999-09-23 2001-03-29 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
WO2003077882A2 (en) * 2002-03-18 2003-09-25 Labopharm Inc. Preparation of sterile stabilized nanodispersions
WO2004039351A2 (en) * 2002-10-31 2004-05-13 Maria Rosa Gasco Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
US20060188566A1 (en) * 2005-02-24 2006-08-24 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Also Published As

Publication number Publication date
AU2008346121B2 (en) 2013-10-10
UA100543C2 (ru) 2013-01-10
CN101909614B (zh) 2015-04-15
ZA201004450B (en) 2011-03-30
CO6290681A2 (es) 2011-06-20
DK2231144T3 (da) 2014-10-13
EP2853264A1 (en) 2015-04-01
AU2008346121A1 (en) 2009-07-16
JP5937180B2 (ja) 2016-06-22
CN101909614A (zh) 2010-12-08
EA201070793A1 (ru) 2010-12-30
JP2015110565A (ja) 2015-06-18
JP5656643B2 (ja) 2015-01-21
KR101505419B1 (ko) 2015-03-30
BRPI0821514A2 (pt) 2016-09-27
WO2009087678A3 (en) 2009-09-11
PL2231144T3 (pl) 2014-12-31
MX2010007076A (es) 2010-09-30
CA2710525A1 (en) 2009-07-16
AP2895A (en) 2014-05-31
ES2509490T3 (es) 2014-10-17
CA2710525C (en) 2017-08-22
US20140030352A1 (en) 2014-01-30
EP2231144A4 (en) 2011-01-12
KR20100112564A (ko) 2010-10-19
NZ586343A (en) 2012-03-30
BRPI0821514B8 (pt) 2021-05-25
AP2010005314A0 (en) 2010-08-31
US20100297244A1 (en) 2010-11-25
JP2011507946A (ja) 2011-03-10
EP2231144A2 (en) 2010-09-29
IL206584A0 (en) 2010-12-30
BRPI0821514B1 (pt) 2020-03-10
WO2009087678A2 (en) 2009-07-16
US8586062B2 (en) 2013-11-19
EP2231144B1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
JP5937180B2 (ja) ナノ分散体
Jing et al. A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel
US8778364B2 (en) Nanodispersion of a drug and process for its preparation
KR20110036075A (ko) 안정한 주입 가능 수중유형 도세타셀 나노에멀젼
WO2012028101A1 (zh) 一种难溶性药物的液体组合物及其制备方法
JP7561629B2 (ja) 不溶性薬物用の水性製剤
WO2009123595A1 (en) Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
CN105853403A (zh) 一种紫杉醇棕榈酸酯脂质体及其制备方法
CN114796111A (zh) 一种含有难溶性药物的浓缩液以及由其制备的乳剂
Kawish et al. Docetaxel-loaded borage seed oil nanoemulsion with improved antitumor activity for solid tumor treatment: Formulation development, in vitro, in silico and in vivo evaluation
US20220347096A1 (en) Liposomal cannabinoids and uses thereof
Thotakura et al. Promises of lipid-based drug delivery systems in the management of breast cancer
Liu et al. PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity
CN101035511B (zh) 形成非层状分散体的组合物
Liu et al. A comprehensive preclinical evaluation of intravenous etoposide lipid emulsion
Zulfakar et al. Medium-Chain Triacylglycerols (MCTs) and Their Fractions in Drug Delivery Systems: A Systematic Review
BR102017015966A2 (pt) Nanocarreadores emulsionados catiônicos multifuncionais e usos dos mesmos
Johnson Amphotericin B Nano-Formulations: Development, characterisation and suitability for oral administration

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM